Hiring in life sciences? Share your open positions with our professional community. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Baxdrostat: First Approval.

Created on 21 Aug 2026

Authors

Hannah A Blair

Published in

Drugs. Aug 21, 2026. Epub Aug 21, 2026.

Abstract

Baxdrostat (BAXFENDY™) is a first-in-class, highly selective and potent aldosterone synthase inhibitor being developed by AstraZeneca for the treatment of hypertension, chronic kidney disease (CKD) and primary aldosteronism, and for the prevention of heart failure. On 15 May 2026, baxdrostat received its first approval in the USA for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure (BP) in adults who are not adequately controlled on other agents. This article summarizes the milestones in the development of baxdrostat leading to this first approval for hypertension.

PMID:
42625106
Bibliographic data and abstract were imported from PubMed on 21 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Sign in to post a review. Add review
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement